Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global metastatic lung adenocarcinoma treatment market size was estimated at USD 4.4 billion in 2023 and is projected to grow at a CAGR of 11.3% from 2024 to 2030. This growth is attributed to the rising global incidence of lung cancer, development of innovative treatment options, and increased awareness and screening programs. According to the World Cancer Research Fund International, 2,480,675 new cases of lung cancer were reported in 2022. The National Institutes of Health highlights that approximately 50.0% of lung cancer cases are metastatic at diagnosis. Metastases from non-small cell lung cancer (NSCLC) frequently involve the brain (47.0%), liver (22.0%), bone (36.0%), thoracic cavity (11.0%), adrenal glands (15.0%), and distant lymph nodes (10.0%), while metastases to other organs are rare, occurring in less than 5.0% of cases.

Metastatic lung adenocarcinoma is a form of lung cancer that spreads from the lungs to other parts of the body. According to the World Health Organization, lung cancer is primarily classified into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), with adenocarcinoma being a subtype of NSCLC that originates from epithelial cells.  Lung cancer is anticipated to cause approximately 125,070 deaths, making it the leading cause of cancer mortality and accounting for about 20.0% of overall cancer deaths.

The disease predominantly affects older adults, with most diagnoses occurring in individuals aged 65 or older, and an average diagnosis age of 70. Very few cases are diagnosed in those younger than 45. These statistics highlight the profound impact of lung cancer and underscore the urgent need for effective treatment options. A 2023 report by the Lung Cancer Research Foundation reveals that 1 in 16 people will be diagnosed with lung cancer in their lifetime, with the risk being slightly higher for men (6.2%) compared to women (5.8%).

The increase in smoking rates, along with environmental factors such as air pollution and occupational exposures, are contributing to the growing incidence of metastatic lung adenocarcinoma worldwide. According to the National Cancer Institute, smoking is the primary risk factor for lung cancer, with smokers facing a tenfold higher risk than those who have smoked fewer than 100 cigarettes in their lifetime. Studies indicate that long-term survivors of smoking-related lung cancer are particularly vulnerable to secondary malignancies, with some research showing a 10.0% risk for second lung cancer and a 20.0% risk for any other recurring cancer. This enduring risk underscores the need for ongoing monitoring and effective treatment strategies.

Moreover, introduction of targeted therapies and immunotherapies has revolutionized the management of metastatic lung adenocarcinoma, offering more effective and personalized treatment options. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have shown efficacy in patients with specific genetic mutations, such as EGFR and ALK. Meanwhile, immunotherapies, including immune checkpoint inhibitors such as pembrolizumab and nivolumab, have provided new avenues for treating patients who are not candidates for targeted therapies. These advancements have not only improved survival rates but also enhanced the quality of life for patients, further driving market demand.

Market Concentration & Characteristics

Degree of innovation in the metastatic lung adenocarcinoma treatment market is high, driven by advancements in targeted therapies and immunotherapies. Advances in molecular diagnostics and genomic profiling have led to the emergence of personalized treatment approaches, enhancing the efficacy of therapies. New-generation TKIs and immune checkpoint inhibitors are at the forefront of these innovations, offering improved survival rates and better management of the disease. For instance, in April 2024, the FDA approved alectinib (Alecensa) as adjuvant therapy in patients diagnosed with anaplastic lymphoma kinase (ALK) - positive NSCLC after tumor resection.

Mergers and acquisitions (M&A) in the metastatic lung adenocarcinoma treatment market are moderate, fueled by the strategic drive to expand product portfolios and integrate advanced technologies. Leading pharmaceutical companies are acquiring biotech firms with strong oncology pipelines to enhance their market presence and accelerate the development of innovative treatments. For instance, in July 2021, AstraZeneca acquired Alexion Pharmaceuticals, Inc. for approximately USD 39.0 billion. This acquisition nurtured AstraZeneca’s capabilities in immunology and rare diseases, particularly with Alexion's expertise in complement biology, aligning with AstraZeneca's broader strategy to address unmet medical needs in these critical areas.

Regulations and regulatory bodies play a crucial role in shaping the metastatic lung adenocarcinoma treatment market. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set stringent guidelines for drug approval, ensuring that new treatments meet safety and efficacy standards. Programs such as the FDA’s Breakthrough Therapy Designation and EMA’s Priority Medicines (PRIME) scheme are designed to expedite the approval process for innovative therapies, thus facilitating quicker patient access to advanced treatments.

Regional expansion in the Metastatic Lung Adenocarcinoma Treatment market is identified at a medium level, with pharmaceutical companies increasingly targeting emerging markets alongside established regions such as North America and Europe. The APAC region has emerged as a key area of interest due to its large patient population, increasing healthcare spending, and approvals from regulatory agencies. For instance, in June 2024, AstraZeneca obtained approval in Japan for the use of Tagrisso (osimertinib) in conjunction with pemetrexed and platinum-based chemotherapy as an initial treatment option for adult patients diagnosed with locally advanced or metastatic NSCLC that is characterized by mutations in the epidermal growth factor receptor (EGFR), specifically those involving exon 19 deletions or the L858R mutation found in exon 21.

Treatment Insights

In 2023, the chemotherapy segment accounted for the largest revenue share of 33.2% in metastatic lung adenocarcinoma treatment market. While immunotherapies are gaining traction, chemotherapy remains essential, particularly for patients who are not eligible for targeted therapies or immunotherapy. According to the study published by National Institute of Health in June 2023, lung adenocarcinoma causes approximately 40.0% of lung cancer cases, ensuring a significant patient base that continues to rely on chemotherapy.

Research has shown that chemotherapy, often used in combination with other treatments, can improve survival rates and manage symptoms effectively in advanced stages. For instance, the POSEIDON Phase III trial, conducted by AstraZeneca in May 2021, showed that combining IMFINZI and IMJUDO with chemotherapy provided over twice the long-term clinical benefit compared to chemotherapy alone. In addition, the Phase III FLAURA2 trial revealed that adding chemotherapy to TAGRISSO significantly improved progression-free survival (PFS) over TAGRISSO monotherapy. These findings reinforce chemotherapy's critical role in treating metastatic lung adenocarcinoma, particularly when integrated with advanced therapeutic.

The immunotherapy segment is experiencing a CAGR of 14.3% within the metastatic lung adenocarcinoma treatment market. Immunotherapies, including immune checkpoint inhibitors, have significantly transformed cancer treatment by leveraging the body's immune system to target cancer cells. The rising incidence of lung adenocarcinoma and the urgent need for effective treatments in advanced stages are key factors driving this growth. Advances in tumor biology and immune response understanding have also contributed to the development of more personalized and effective immunotherapies. Chemotherapy was the standard treatment until 2015, when KEYTRUDA (pembrolizumab) was approved as a second-line treatment, followed by TECENTRIQ (atezolizumab) in 2016. These therapies later expanded to first-line treatments. In 2020, OPDIVO (nivolumab) combined with ipilimumab was approved as a first-line treatment for patients with metastatic NSCLC.

End Use Insights

Hospitals accounted for the largest revenue share of 64.3% in 2023. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care. They offer comprehensive services, including surgery, chemotherapy, radiation, and immunotherapy, under one roof, which is crucial for managing advanced stages of lung adenocarcinoma. In addition, hospitals often participate in clinical trials, providing access to cutting-edge therapies not available elsewhere. As per the National Library of Medicine, hospitals with multidisciplinary teams achieve better outcomes in cancer treatment due to coordinated care and access to specialized services. Moreover, the prevalence of metastatic lung adenocarcinoma necessitates frequent hospital visits for ongoing treatment and management, further driving the demand in this segment. The high patient footfall, coupled with the availability of state-of-the-art technology and expertise, solidifies hospitals' dominance in this market.

Specialty clinics are anticipated to achieve the highest CAGR of 15.3% in the metastatic lung adenocarcinoma treatment market during the forecast period, driven by growing demand for personalized and targeted therapies and heightened patient awareness about treatment options. These clinics are dedicated to managing specific cancer types, offering customized treatment plans that integrate the latest advancements in therapy, such as immunotherapy and targeted treatments. In addition, specialty lung cancer clinics are increasingly incorporating innovative techniques such as liquid biopsies, which enhance early detection and ongoing monitoring of treatment responses. This focus on specialized, cutting-edge care is meeting the evolving needs of patients and contributing significantly to the rapid growth of specialty clinics in the oncology sector.

Regional Insights

The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors. According to a 2023 report by the Lung Cancer Research Foundation, approximately 654,620 people in the U.S. have been diagnosed with lung cancer at some point in their lives. In addition, pharmaceutical companies actively engage in mergers and acquisitions to broaden their product offerings and bolster research capabilities. Regulatory bodies, including the FDA, support this progress through expedited approval processes. For example, in March 2022, the FDA approved Opdivo (nivolumab) combined with chemotherapy as a neoadjuvant treatment for specific resectable non-small cell lung cancer (NSCLC) cases, reflecting the market's dynamic evolution.

U.S. Metastatic Lung Adenocarcinoma Treatment Market Trends

The UK metastatic lung adenocarcinoma treatment market is characterized by its high prevalence and rapid adoption of new treatments. Lung cancer, particularly adenocarcinoma, is the second most common cancer in the U.S., with an estimated 234,580 new cases and around 125,070 deaths in 2024, according to the American Cancer Society report published in January 2024. This significant patient population drives substantial demand for advanced therapies. The FDA supports this demand with regulatory initiatives such as Fast Track and Breakthrough Therapy designations, which expedite the approval of innovative treatments.

The metastatic lung adenocarcinoma treatment market in Canada is shaped by the high prevalence of the disease and a supportive regulatory framework. Lung cancer remains the leading cause of cancer-related deaths in Canada, with non-small cell lung carcinoma (NSCLC) representing 85% of these cases. According to the Canadian Cancer Society, approximately 32,100 new cases of lung and bronchus cancer are expected in 2024, accounting for 13% of all new cancer diagnoses. This type of cancer is projected to cause 23% of cancer-related deaths, with an estimated 20,700 fatalities. The statistics indicate that 14,800 men and 17,300 women will be diagnosed, and 10,900 men and 9,800 women are anticipated to die from the disease. On a daily basis, this translates to 88 new diagnoses and 57 deaths, underscoring the critical need for effective treatment options and the impact of ongoing regulatory and healthcare initiatives.

Europe Metastatic Lung Adenocarcinoma Treatment Market Trends

The metastatic lung adenocarcinoma treatment market in Europe is growing rapidly due to high disease prevalence and supportive regulatory frameworks. According to the European Commission, lung cancer is one of the major health issues in Europe, with over 319,000 new cases of lung cancer reported in 2023. The European Medicines Agency (EMA) supports market growth by providing regulatory pathways that facilitate the approval and availability of new therapies. This high incidence drives the demand for advanced treatment options.

The metastatic lung adenocarcinoma treatment market in the UK is bolstered by a high prevalence of the disease and proactive healthcare measures. According to Cancer Research UK, lung cancer is the third most common cancer, representing 13.0% of all new cancer diagnoses, with approximately 49,200 new cases annually. The National Health Service (NHS) enhances market growth through strategic initiatives such as the Cancer Drugs Fund, which ensures patients have access to cutting-edge therapies. These efforts contribute to the advancement and availability of novel treatments, addressing the significant need within the UK healthcare system.

The metastatic lung adenocarcinoma treatment market in France is strongly supported by government-backed R&D efforts aimed at tackling cancer. According to an October 2022 study by the National Library of Medicine, lung cancer ranks as the second most common cancer among men and the third most common among women in France. The French National Cancer Institute plays a crucial role in advancing the field by funding groundbreaking research into new therapies, including immunotherapy and gene therapy specifically designed for lung adenocarcinoma. In addition, the Haute Autorité de Santé (HAS) facilitates faster access to innovative treatments through streamlined approval processes, further enhancing patient care and treatment options in country.

Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Trends

The metastatic lung adenocarcinoma treatment market in APAC region is experiencing rapid growth due to high prevalence of the disease and increasing investments in healthcare. Lung cancer remains the most common cancer and the leading cause of cancer-related deaths in the region. According to the World Health Organization (WHO), lung cancer is responsible for approximately 1.8 million deaths annually, accounting for 18.7% of all cancer fatalities, with tobacco use in Asia being a significant factor for its high incidence. The region is making substantial strides in healthcare infrastructure and regulatory processes. Key regulatory bodies, such as the China National Medical Products Administration (NMPA) and the Japan Pharmaceuticals and Medical Devices Agency (PMDA), are actively expediting the approval of new therapies. These advancements are enhancing the availability of innovative treatments for metastatic lung adenocarcinoma, contributing to the market's expansion and improving patient outcomes across the Asia Pacific region.

The Japan metastatic lung adenocarcinoma treatment market is influenced by a strong emphasis on advanced therapeutic options and high healthcare standards. The Japanese government implements favorable regulatory pathways that encourage the development of new drugs, particularly those targeting specific biomarkers like EGFR mutations.  For instance, in March 2023, Ono Pharmaceutical Co., Ltd. secured additional approval for Opdivo in combination with chemotherapy as a neoadjuvant treatment for NSCLC in Japan. Furthermore, Japan’s aging population presents unique challenges and opportunities; as older adults are more susceptible to lung cancer, there is an urgent need for effective treatments tailored to this demographic. 

The metastatic lung adenocarcinoma treatment market in China is significantly influenced by the high prevalence of the disease and robust government and regulatory support. According to the Shanghai Municipal People's Government, lung cancer is the most common and deadliest cancer in China, with approximately 800,000 new cases reported annually and around 70.0% of patients are diagnosed at advanced or terminal stages, highlighting an urgent need for effective treatments. In response, the Chinese government has prioritized cancer care through initiatives such as the "Healthy China 2030" plan, which focuses on improving cancer research, treatment accessibility, and patient outcomes. In addition, the National Medical Products Administration (NMPA) has streamlined approval processes for innovative therapies, including targeted and immunotherapies, to address the high demand and improve treatment options for patients with metastatic lung adenocarcinoma.

Latin America Metastatic Lung Adenocarcinoma Treatment Market Trends

The metastatic lung adenocarcinoma treatment market in Latin America is expanding due to increasing cancer incidence and evolving healthcare infrastructure. According to the International Agency for Research on Cancer (IARC), lung cancer is among the top three cancer types in several Latin American countries. In addition, the need for effective treatment options are driving investments in R&D, leading to the launch of new therapies tailored to the specific needs of the Latin American population.

The metastatic lung adenocarcinoma treatment market in Brazil is driven by a high prevalence of lung cancer and supportive healthcare initiatives. Lung cancer is a major health concern in Brazil, with over 30,000 new cases reported annually and smoking accounting for 80.0% of deaths linked to lung cancer, as per the Brazilian National Cancer Institute (INCA). The Brazilian government is focusing on improving cancer care through initiatives like the National Cancer Control Program, which aims to enhance early detection and treatment access. The Agência Nacional de Vigilância Sanitária (ANVISA) plays a crucial role in expediting the approval of new drugs, including innovative therapies such as targeted agents and immunotherapies.

Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market Trends

The metastatic lung adenocarcinoma treatment market in the Middle East and Africa is witnessing significant growth driven by an increase in lung cancer incidence, particularly due to rising smoking rates and environmental factors. According to the Tobacco Atlas, Lebanon held the highest smoking rate in the Middle East, with each person smoking an average of 1,955 cigarettes in 2022. This prevalence witnessed a surge in innovative therapies, including targeted therapies and immunotherapies, which have transformed treatment paradigms. Regulatory bodies are also playing a role in enhancing market growth by facilitating the approval of new therapies. For instance, the Saudi Food and Drug Authority (SFDA) is working to streamline the approval process for innovative treatments, contributing to the expansion of treatment options for metastatic lung adenocarcinoma patients.

The Saudi Arabia metastatic lung adenocarcinoma treatment market is characterized by rapid advancements in healthcare infrastructure, increased investment in oncology research and supportive government initiatives. The government’s Vision 2030 initiative aims to enhance healthcare services and promote medical innovation, which led to collaborations between public health institutions and pharmaceutical companies.

Key Metastatic Lung Adenocarcinoma Treatment Company Insights

The metastatic lung adenocarcinoma treatment market is dominated by several major pharmaceutical companies that collectively account for a significant market share. These leading players established themselves through extensive research and development efforts, resulting in the introduction of innovative targeted therapies and immunotherapies. They also expanded their product portfolios through strategic collaborations, mergers, and acquisitions. 

Recent Developments

• In March 2024, Bristol Myers Squibb (BMS) reported that its Phase III KRYSTAL-12 clinical trial evaluating KRAZATI (adagrasib) for patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutations has successfully achieved its primary objectives.

• In February 2024, AstraZeneca's Tagrisso (osimertinib) received approval in the U.S. for use with chemotherapy to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor mutations (EGFRm). This approval represents a significant advancement in the treatment of EGFR-mutated NSCLC, offering a more comprehensive approach by combining targeted therapy with chemotherapy to improve patient outcomes in advanced stages of the disease.

• In November 2023, the U.S. Food and Drug Administration (FDA) approved repotrectinib (AugtyroTM) for treating advanced ROS-1 fusion non-small cell lung cancer (NSCLC). This approval was grounded in the promising results from the TRIDENT-1 trial, which were later published in The New England Journal of Medicine on January 11, 2024. The trial demonstrated repotrectinib’s effectiveness in targeting ROS-1 fusion, offering a new, targeted therapy option for patients with advanced NSCLC.

• In March 2022, Bristol Myers Squibb acquired Turning Point Therapeutics, enhancing its oncology portfolio with repotrectinib, a promising next-generation ROS1/NTRK inhibitor aimed at treating patients with ROS1-positive Non-Small Cell Lung Cancer.

Metastatic Lung Adenocarcinoma Treatment Market Report Scope

Global Metastatic Lung Adenocarcinoma Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global metastatic lung adenocarcinoma treatment market report based on treatment, end use and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Targeted Therapy

  • Immunotherapy

  • Radiation Therapy

  • Other

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Specialty Clinics

  • Other

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait